- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Renal cell carcinoma (RCC)
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Cabozantinib – March 2020
Cabozantinib: Tablet 20 mg, Tablet 40 mg, Tablet 60 mg; Cabometyx®
Last updated
3 July 2020